179687-02-6

Basic information

• Product Name: (2-chloro-4-nitrophenyl)(pyridin-2-yl)methanol
• Synonyms: (2-chloro-4-nitrophenyl)(pyridin-2-yl)methanol
• CAS NO: 179687-02-6
• Molecular Weight: 264.668
• Mol File: 179687-02-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2-chloro-4-nitrophenyl)(pyridin-2-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-chloro-4-nitrophenyl)(pyridin-2-yl)methanol(179687-02-6)
• EPA Substance Registry System: (2-chloro-4-nitrophenyl)(pyridin-2-yl)methanol(179687-02-6)

Safety Data

• Hazardous Substances Data: 179687-02-6(Hazardous Substances Data)

Upstream product

• 1121-60-4 pyridine-2-carbaldehyde 
• 109-72-8 n-butyllithium 
• 41252-96-4 3-chloro-4-iodonitrobenzene 
• 7073-36-1 2-chloro-4-nitrobenzoyl chloride 
• 52301-88-9 (2-chloro-4-nitrophenyl)methanol 
• 109-04-6 2-bromo-pyridine 
• 5568-33-2 2-chloro-4-nitrobenzaldehyde 

Downstream Products

• 497854-61-2 (4-amino-2-chlorophenyl)(pyridin-2-yl)methanol 

Relevant articles and documents

Orally active CCR5 antagonists as anti-HIV-1 agents 2: Synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety

In order to develop orally active CCR5 antagonists, we investigated 1-benzoxepine derivatives containing new polar substituents, such as phosphonate, phosphine oxide or pyridine N-oxide moieties, as replacements for the previoiusly reported quaternary ammonium moiety. Among these compounds, the 2-(α-hydroxybenzyl)pyridine N-oxide 5e exhibited moderate CCR5 antagonistic activity and had an acceptable pharmacokinetic profile in rats. Subsequent chemical modification was performed and compound (S)-5f possessing the (S)-configuration hydroxy group was found to be more active than the (R)-isomer. Replacement of the 1-benzoxepine ring with a 4-methylphenyl group by a 1-benzazepine ring with a 4-[2-(butoxy)ethoxy]phenyl group enhanced the activity in the binding assay. In addition, introduction of a 3-trifluoromethyl group on the phenyl group of the anilide moiety led to greatly increased activity in the HIV-1 envelope-mediated membrane fusion assay. In particular, compound (S)-5s showed the most potent CCR5 antagonistic activity (IC 50=7.2 nM) and inhibitory effect (IC50=5.4 nM) in the fusion assay, together with good pharmacokinetic properties in rats.

Aniline derivatives

The invention concerns aniline derivatives of formula I STR1 wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R1 and R2 are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.